文献速递淋巴瘤

TP53异常的慢性淋巴细胞白血病接受一线布鲁顿酪氨酸激酶抑制剂为基础治疗的回顾性分析

TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis.
PubMed 文献 · Am J Hematol · 2022-05-30

该回顾性分析纳入130例基线存在del(17p)和/或TP53突变的慢性淋巴细胞白血病患者,一线接受BTKi联合或不联合维奈克拉及CD20抗体治疗,4年无进展生存率和总生存率分别为72.9%和83.6%。低负荷TP53异常(del(17p)细胞<25%或TP53突变VAF<10%)患者结局与高负荷者相似,提示评估基因组风险时不应忽视低负荷TP53异常。

要点

  • 130例TP53异常CLL患者一线BTKi治疗4年PFS率72.9%、OS率83.6%。
  • del(17p)细胞<25%或TP53突变VAF<10%的低负荷患者结局与高负荷者相似。
  • 基线特征包括IGHV突变状态和TP53异常数目均与PFS或OS无显著差异。

核心结论

  • 在靶向治疗时代评估CLL基因组风险时不应忽视低负荷TP53异常。

研究设计与样本

  • 回顾性分析130例基线存在del(17p)和/或TP53突变的CLL患者,一线接受BTKi联合或不联合维奈克拉及CD20抗体治疗。

主要发现

  • 104/130(80%)例患者存在del(17p);89/110(81%)例受检患者检出TP53突变,其中101个独特TP53突变有可用的VAF。
  • 4年无进展生存率和总生存率分别为72.9%和83.6%。
  • 包括IGHV突变状态和TP53异常数目在内的基线特征均与PFS或OS无显著差异,但核型复杂度增加与PFS缩短呈趋势(风险比1.08,p=0.066)。
  • 26/104(25%)例患者del(17p)细胞<25%,28/101(28%)例TP53突变VAF<10%,这些低负荷患者的结局与高负荷病变患者相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Long-term follow up of prospective studies has shown that continuous Bruton's tyrosine kinase inhibitor (BTKi) therapy leads to durable remissions in previously untreated patients with TP53-altered chronic lymphocytic leukemia (CLL); however, it is unknown how variant allele frequency (VAF) of TP53 mutation (TP53-m) or percentage of cells with deletion of chromosome 17p [del(17p)] influences efficacy of firstline BTKi. We performed a retrospective analysis of 130 patients with CLL with baseline del(17p) and/or TP53-m treated with BTKi with or without the BCL2 inhibitor venetoclax (VEN) and with or without CD20 antibody in the firstline setting. A total of 104/130 (80%) patients had del(17p). TP53-m was noted in 89/110 (81%) patients tested; there were 101 unique TP53-m with an available VAF. The 4-year progression-free survival (PFS) and overall survival (OS) rates were 72.9% and 83.6%. No baseline characteristics including IGHV mutation status and number of TP53 alterations were associated with significant differences in PFS or OS, though a trend toward shorter PFS with increasing karyotypic complexity (hazard ratio 1.08, p = .066) was observed. Del(17p) was identified in <25% of cells in 26/104 (25%) of patients, and 28/101 (28%) of TP53-m were low-burden with a VAF of <10%; outcomes of these patients were similar to those with high-burden lesions. This study suggests that low-burden TP53 alterations should not be ignored when assessing genomic risk in CLL in the era of targeted therapy.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Cherng HJ, Khwaja R, Kanagal-Shamanna R, et al. TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. Am J Hematol. 2022. PMID: 35567779. doi:10.1002/ajh.26595

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。